Infection prevention biotech with late-stage assets targeting C. difficile and post-surgical S. aureus infections.
UK
Joined September 2011
- Tweets435
- Following239
- Followers533
- Likes31
US FDA grant Destiny QIDP designation for XF-73 Dermal Gel, for treatment and prevention of Staphylococcal (inc MRSA) burn wound infections. This adds to the previous QIDP award for XF-73 Nasal, preventing post-surgical Staphylococcal (inc MRSA) infections
bit.ly/4dXEiGg
Destiny Pharma will deliver an oral presentation on its clinical trial of XF-73 nasal in cardiac surgery patients at the ESCMID congress in Porto, 17-20 Sept 2024, themed as ‘Meeting the challenge of antimicrobial resistance’, for press release click below
bit.ly/4dQLaFi
Destiny announces initiation of a research project, with the US Cystic Fibrosis Foundation, evaluating the potency of Destiny’s XF drugs against a range of MRSA clinical isolates, from patients with cystic fibrosis in the US. Click to read press release
bit.ly/3X0H2gy
New data on Destiny's lead drug, XF-73, has been accepted for presentation at the Infection Prevention Society conference in September 2024. To read the press release, click on link below
bit.ly/3YPQ8y7
#DEST #XF73 #IP2024
Great news that further data from our XF-73 Nasal Phase 2b study has been accepted for presentation at ID Week, a leading US infectious disease conference, in October 2024 (bit.ly/3Lz0yKl)
WHO says, “Antimicrobial resistance is only getting worse, yet we're not developing new trailblazing products fast enough”. Destiny’s XF-73 is one such product. #XF73 #DEST #AMR #WHO
bit.ly/3y3N5XX
PEW Charitable Trust raises awareness of the urgent need for new antibiotics. Destiny’s lead candidate, XF-73, is addressing this need.
bit.ly/4cvqZvV
#PEW #DEST #XF73 #AMR
Destiny announce XF-70 potency in an in vivo ringworm model, a fungal skin infection, affecting up to 25% of people. Data to be presented @ bit.ly/4c7g9MY XF-70 is related to XF-73 (P3 ready asset, to prevent post-surgical MRSA infection) bit.ly/3z7dqEC
Encouraging step forward in the fight against AMR. XF-73 Nasal receives MHRA Innovation Passport which will expedite market access for life-threatening/debilitating conditions with significant patient/public health need signifies vote of support from MHRA bit.ly/4bdkWvf
Rise of drug resistant superbugs could make COVID-19 pandemic look minor” warns UK's special envoy on AMR. "This issue is more acute than climate change and it's already claiming 1.2m lives a year."
Underlining the need for Destiny's XF-73 product.
bit.ly/3QKLr3o
The UK's 2nd 5-yr national action plan sets out ambitions to support the 20-year vision for AMR. Destiny aligns with the plan. Our lead candidate, XF-73 Nasal, is being developed for prevention of post-surgical SA infections & is ready to enter P3 trials bit.ly/4bAPHL7
Destiny announces its audited financial results for year ended 31 December 2023. The company also announced commencement of a strategic options review to support the company’s advancement of XF-73 nasal through P3 clinical trials.
bit.ly/3Ud6qgf
Destiny Pharma today provides a clinical development update on two of its programmes, XF-73 Dermal and NTCD-M3. Click on the link below to read the full press release
bit.ly/49yy1ij
Single course of antibiotics increases blood infection risk by 70% study discovers. Destiny Pharma's innovative medicines can replace and reduce the use of antibiotics.
bit.ly/3RizJxD
Destiny Pharma is attending the ‘Tackling Antimicrobial Resistance in Hospital Settings’ webinar today. Destiny is addressing the global AMR challenge, developing novel anti-infectives focusing on infection prevention, rather than just infection treatment. bit.ly/47ywxTT
